<DOC>
	<DOCNO>NCT01354665</DOCNO>
	<brief_summary>This study aim evaluate occurence severity fatigue depression multiple sclerosis patient impact Betaferon treatment symptom alteration . The study conduct routine practice set hence interference standard care take place . Pharmacologic treatment MS-fatigue depression also record .</brief_summary>
	<brief_title>Depression Fatigue MS Patients Treated With Betaferon .</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Relapsingremitting multiple sclerosis Age 18+ Patients initiate Betaferon treatment Patients previously treat immunomodulatory drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Interferon beta-1b</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Depression</keyword>
</DOC>